Phase I study of TRXE 002 (Cantrixil) as a potential therapy for treatment-resistant cancer that has arisen within the abdomen or has metastasised there.

Trial Profile

Phase I study of TRXE 002 (Cantrixil) as a potential therapy for treatment-resistant cancer that has arisen within the abdomen or has metastasised there.

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2016

At a glance

  • Drugs TRXE 002 (Primary)
  • Indications Colorectal cancer; Malignant ascites; Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Mar 2016 According to a Novagen media release, this trial is scheduled to begin in the second half of 2016.
    • 29 Jul 2015 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2016 according to a Novagen media release.
    • 29 Jul 2015 This trial is scheduled to begin in 2016 according to a Novagen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top